Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease.
Women undergoing chemotherapy for breast cancer are often administered dopamine antagonist adjuvant medications that may increase levels of prolactin potentially increasing the risk of cancer. Using nationwide computerized registers of death data for the years 1991 through 1996 we examined 12,430,473 deaths of persons over 40 years of age and extracted 144,364 cases with Parkinson's disease (PD), a dopamine deficient population. Patients with PD had lower rates of breast and other types of malignancies, even in the presence of depression and suicide.
Lalonde
François M
FM
Geriatric Psychiatry Branch, NIMH, NIH, Bethesda, MD, USA.
Myslobodsky
Michael
M
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D018492:Dopamine Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D011388:Prolactin / Q000097:blood*; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D014481:United States / Q000453:epidemiology
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011388:Prolactin